Your browser doesn't support javascript.
loading
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
Zhu, Fengcai; Jin, Pengfei; Zhu, Tao; Wang, Wenjuan; Ye, Huayue; Pan, Hongxing; Hou, Lihua; Li, Jingxin; Wang, Xue; Wu, Shipo; Wang, Ying; Gou, Jinbo; Huang, Haitao; Wu, Hongbin; Wang, Xuewen; Chen, Wei.
  • Zhu F; Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Jin P; National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Zhu T; Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Wang W; CanSino Biologics, Tianjin, China.
  • Ye H; Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Pan H; Taizhou Center for Vaccine Clinical Research, Taizhou, China.
  • Hou L; Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Li J; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Wang X; Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Wu S; National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China.
  • Wang Y; CanSino Biologics, Tianjin, China.
  • Gou J; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Huang H; CanSino Biologics, Tianjin, China.
  • Wu H; CanSino Biologics, Tianjin, China.
  • Wang X; CanSino Biologics, Tianjin, China.
  • Chen W; Taizhou Center for Vaccine Clinical Research, Taizhou, China.
Clin Infect Dis ; 75(1): e783-e791, 2022 08 24.
Article en En | MEDLINE | ID: mdl-34551104
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas Virales / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas Virales / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Humans Idioma: En Año: 2022 Tipo del documento: Article